G von Minckwitz - Concepedia

Author

G von Minckwitz

Also Known As

G Minckwitz, G von Minckwitz, G von Minckwitz, G. VON MINCKWITZ, G. Von Minckwitz, G. von Minckwitz, G. von minckwitz, Gunter von Minckwitz, von Minckwitz, G.

113

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

German Breast group Universitäts Frauenklinik Helios Hospital Berlin-Buch Heidelberg University Goethe University Frankfurt

About

G von Minckwitz is an author at German Breast group specializing in medicine, breast cancer, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	818
2	Health Sciences	6	6	188
3	Cell Biology	3	3	297
4	Nursing	1	1	91
5	Biochemistry	1	1	92

G von Minckwitz

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial G von Minckwitz, Sherko Kümmel, P. Vogel, JNCI Journal of the National Cancer Institute	2008	293
Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Peter Dall, Karl‐Heinz Heider, Armin Hekele, PubMed ImmunologyPathologyUterine Cervical CancerCancer BiologyTumor Biology	1994	124
The role of early expression of inducible nitric oxide synthase in human breast cancer Sibylle Loibl, Angela Buck, Cornelia Strank, European Journal of Cancer Breast OncologyBiochemistryReactive Nitrogen SpecieNitrosative StressEarly Expression	2004	92
Breast cancer patients' expectations in respect of the physician–patient relationship and treatment management results of a survey of 617 patients Gülten Oskay-Özcelik, Walter Lehmacher, Dominique Könsgen, Annals of Oncology NursingFamily MedicinePatient ExperienceBreast Cancer PatientsMedicine	2007	91
Methylation of estrogen receptor β promoter correlates with loss of ER-β expression in mammary carcinoma and is an early indication marker in premalignant lesions Achim Rody, Uwe Holtrich, Christine Solbach, Endocrine Related Cancer Breast OncologyGynecologyPathologyEpigeneticsTumor Biology	2005	81
Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials RE Coleman, Michael Gnant, AlexanderH.G. Paterson, Cancer Research Breast OncologyIndividual Patient DataDistant RecurrenceGynecologyBisphosphonate Treatment	2013	62
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765) Aurelia Noske, Sibylle Loibl, Silvia Darb‐Esfahani, Breast Cancer Research and Treatment Mrna LevelBreast OncologyHer2 ExpressionChemotherapy ResponseMedicine	2010	57
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial Isabell Witzel, Sibylle Loibl, G von Minckwitz, Breast Cancer Research and Treatment Serum Her2 LevelsOncologyGeparquattro TrialNeoadjuvant Trastuzumab TreatmentClinical Trials	2010	49
Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast. Ralf Hildenbrand, Charlotte H. J. R. Jansen, G Wolf, PubMed	1998	49
S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients – Results of the GeparTrio Trial. G von Minckwitz, Serban Dan Costa, Carsten Denkert, Cancer Research Breast OncologyMedicineCancer ManagementInterim ResponseClinical Trials	2011	41

Page 1